Enochian Biosciences, Inc. (ENOB) Income Statement Analysis

See more : Leader Harmonious Drive Systems Co., Ltd. (688017.SS) Income Statement Analysis – Financial Results

Complete financial analysis of Enochian Biosciences, Inc. (ENOB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enochian Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Austin Engineering Company Limited (AUSTENG.BO) Income Statement Analysis – Financial Results
Tracxn Technologies Limited (TRACXN.BO) Income Statement Analysis – Financial Results
Yokogawa Electric Corporation (6841.T) Income Statement Analysis – Financial Results
Joint-Stock Company Ryazanenergosbyt (RZSB.ME) Income Statement Analysis – Financial Results
Gemdale Properties and Investment Corporation Limited (0535.HK) Income Statement Analysis – Financial Results

Enochian Biosciences, Inc. (ENOB)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.enochianbio.com

About Enochian Biosciences, Inc.

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2012	2011
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	42.77K	0.00	0.00	0.00
Cost of Revenue	121.86K	113.50K	123.59K	391.42K	366.27K	71.71K	18.48K	14.53K	32.67K	314.64K	0.00	0.00
Gross Profit	-121.86K	-113.50K	-123.59K	-391.42K	-366.27K	-71.71K	-18.48K	-14.53K	10.10K	-314.64K	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	23.62%	0.00%	0.00%	0.00%
Research & Development	2.71M	4.17M	8.37M	15.72M	4.69M	2.50M	616.96K	62.76K	804.19K	0.00	0.00	0.00
General & Administrative	24.17M	15.32M	14.33M	7.56M	7.12M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	383.55K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	24.56M	15.32M	14.33M	7.56M	7.12M	8.42M	2.60M	2.32M	1.33M	2.11M	37.09K	29.95K
Other Expenses	54.37M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	81.64M	19.60M	22.83M	23.40M	11.92M	10.92M	3.22M	2.39M	2.13M	2.11M	37.09K	29.95K
Cost & Expenses	81.64M	19.60M	22.83M	23.40M	11.92M	10.99M	3.24M	2.40M	2.16M	2.43M	37.09K	29.95K
Interest Income	0.00	0.00	122.04K	13.18K	50.30K	73.49K	45.82K	0.00	0.00	5.94K	0.00	0.00
Interest Expense	1.01M	706.96K	372.84K	379.61K	104.28K	43.00	143.26K	26.26K	2.36K	84.55K	497.00	0.00
Depreciation & Amortization	121.86K	113.50K	123.59K	123.53K	366.27K	71.71K	18.48K	14.53K	27.40K	45.20K	0.00	0.00
EBITDA	-79.52M	-19.48M	-22.70M	-23.28M	-11.51M	-17.94M	-5.31M	-2.39M	-2.17M	-2.42M	-37.09K	-29.95K
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4,894.99%	0.00%	0.00%	0.00%
Operating Income	-81.64M	-38.56M	-116.08M	-23.40M	-11.92M	-10.99M	-3.24M	-2.40M	-2.12M	-2.43M	-37.09K	-29.95K
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4,959.04%	0.00%	0.00%	0.00%
Total Other Income/Expenses	989.12K	-1.13M	2.65M	-3.45M	507.41K	-7.03M	-3.19M	192.72K	-77.10K	-119.20K	-497.00	0.00
Income Before Tax	-80.65M	-39.68M	-113.43M	-26.85M	-11.42M	-18.02M	-6.42M	-2.21M	-2.20M	-2.55M	-37.59K	-29.95K
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5,139.30%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	706.96K	34.00	-125.28K	104.28K	1.00	-111.72K	-64.88K	-462.79K	-177.54K	0.00	0.00
Net Income	-80.65M	-39.68M	-113.43M	-26.72M	-11.42M	-18.02M	-6.31M	-2.14M	-1.74M	-2.37M	-37.59K	-29.95K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4,057.24%	0.00%	0.00%	0.00%
EPS	-0.84	-0.71	-2.16	-0.57	-0.25	-0.48	-0.29	-0.17	-0.18	-0.32	-0.01	0.00
EPS Diluted	-0.84	-0.71	-2.16	-0.57	-0.25	-0.48	-0.29	-0.17	-0.18	-0.32	-0.01	0.00
Weighted Avg Shares Out	96.25M	56.27M	52.53M	47.17M	46.33M	37.55M	21.94M	12.27M	9.53M	7.50M	5.00M	10.44M
Weighted Avg Shares Out (Dil)	96.25M	56.27M	52.53M	47.17M	46.33M	37.55M	21.94M	12.27M	9.53M	7.50M	5.00M	10.44M

The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

March 10, 2020benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis...

Coronavirus Now in 89 Countries, Over 98,000 Infected, COVID-19 & Influenza Similarities

March 7, 2020scitechdaily.com

Note: There is now a newer Novel Coronavirus (COVID-19) Situation Report 47. WHO Novel Coronavirus (COVID-19) Situation Report 46 4 new countries/territories/areas (Bhutan, Cameroon, Serbia, and South Africa) have reported cases of COVID-19 in the past 24 hours. As the...

The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

February 27, 2020finance.yahoo.com

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate ...